Tuberculosis Research and Treatment / 2018 / Article / Tab 1

Review Article

Is Chemoprophylaxis for Child Contacts of Drug-Resistant TB Patients Beneficial? A Systematic Review

Table 1

Summary of the seven studies showing their relevant details of included parameters.

NumberAuthor Study designTreatment regimenStudy subjectsNumber of childrenTreatment completion rateAdverse eventIncidence TBMortalityFollow-up monthsRemark

Seddon et al. [7] (2013)Prospective cohort 
South Africa
Ofloxacin, ethambutol, and high dose Children < 5 years, CLHIV < 15 years18675.8% (141/186)7/186 (3.7%)6/141 on PT
4/45 not on PT
1 (0.5%)219 p-y (12–24 months)-
Schaaf  et al.
[8] (2002)
Prospective cohort 
S. Africa
High dose isoniazid, pyrazinamide, ethionamide, ethambutol/Children < 5 years old41 + 6430/61 Eth 
1/15 OFX
2/41 on PT 13/64 not on PTNo deaths30-
Adler-Shohet et al. [9] (2014)Prospective cohort 
9 mon levofloxacin and pyrazinamideChildren318/26 (31%) 
(7 changed Rx 
11 did not complete)
All children0No deaths24No separate mention on outcome in those who refused PT
Gracia-Prats et al. [10] (2014)Retrospective 
community cohort 
S. Africa
Ofloxacin, ethambutol, and high dose <15 years3824/34 (71%)NoNo TBNo deaths12PT offered only to HHC < 5 years of age
Bamrah et al.
[11] (2014)
Prospective cohort 
12 mon levofloxacin and ethambutolChildren < 12 years119 
(only 26 children)
25/26 (95%)Not clear0/104 on PT 
3/15 not on PT
No deaths36Not mentioned who developed TB—adult or child
Feja et al.
[12] (2008)
Retrospective chart review
9 mon quinolones, cycloserine, ethionamide, pyrazinamide, ethambutolChildren < 15 years5136/41 (88%) at DOHMH; 2/9 (22%)8/22 (24%)No TBNo deaths24No comparator group without PT
Attamna et al.
[13] (2009)
Retrospective chart review 
Ciprofloxacin and 476 
(387 no Rx versus 89 PT)
Not clearNot clearNo TB in any groupNot clear72Low TB prevalence area

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.